About the Company
Alexion Pharmaceutical, Inc. (NYSE: ALXN) is an American biopharmaceutical company founded in the year 1992. It conducts extensive researches on the immune system and autoimmune diseases. It is headquartered in Massachusetts, US. In 2011, with a market value of $8.5 million, Alexion was added to the NASDAQ-100. ALXN shares reached their all-time high closing price of $207.84 on July 23rd, 2015. As of 2020, the company’s net worth was $24.71 billion.
Alexion Pharmaceutical, Inc. is best known for its development of Soliris, a medicine used to treat rare disorders such as aHUS and PNH. Soliris received approval from the US Food and Drug Administration (FDA) in 2007. In 2010, Germany saw an outbreak of Haemolytic-Uremic Syndrome (HUS) and Soliris was considered as a treatment option. The company also offers speciality drugs for other rare diseases such as gMG, HPP, LAL-D and NMOSD. In addition to Soliris, the company also developed Strensiq – a drug that treats Hypophosphatasia, a rare metabolic disorder. Alexion also acquired Kanuma, a medication for Lysosomal Acid Lipase Deficiency, a fatal genetic disorder. The company’s research segment focuses on the core therapeutic areas of neurology, haematology, metabolics, nephrology and cardiology.
Over the years, Alexion has acquired several leading companies. Some notable acquisitions include Proliferon Inc. in 2000, Enobia Pharma Corp in 2011, Syntimmune in 2018, Achillion Pharmaceuticals in 2019, and Portola in the year 2020. It received the Judge’s Prize in the 2018 Best Practices Award by Bio-IT World for its SmartPanel platform. The company was awarded the 2009 Prix Galien (The Galien Prize) for its Soliris medication. As of 2019, Alexion Pharmaceutical, Inc. ranked 41 in Fortune’s list of Future 50. In 2020, Alexion was also recognised by OSHA (Occupational Safety and Health Administration) for its commitment to workplace health and security. The company ranks 796 on Forbes’ list of Global 2000 2020 companies. It was also included in Forbes’ list of World Best Employers in 2020. As of 2020, the company operates in several regions worldwide like North America, Europe, Middle-East, Latin America, and the Asia-Pacific, among others.;
|Organisation||Alexion Pharmaceuticals Inc|